Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

Gabriel N. Hortobagyi, Aman U. Buzdar, Richard L. Theriault, Vicente Valero, Debra Frye, Daniel J. Booser, Frankie A. Holmes, Sergio Giralt, Issa Khouri, Borje Andersson, James L. Gajewski, Gabriela Rondon, Terry L. Smith, Sonja E. Singletary, Frederick C. Ames, Nour Sneige, Eric A. Strom, Marsha D. McNeese, Albert B. Deisseroth, Richard E. Champlin

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. Patients and Methods: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. Results: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty- nine patients were randomly assigned to FAC and 39 to FAC followed by high- dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P = .35), and 3-year survival rates were 77% and 58%, respectively (P = .23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. Conclusions: No relapse- free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalJournal of the National Cancer Institute
Volume92
Issue number3
StatePublished - Feb 2 2000
Externally publishedYes

Fingerprint

Autografts
Blood Cells
Breast Neoplasms
Drug Therapy
Hematopoietic Stem Cells
Recurrence
Doxorubicin
Cyclophosphamide
Survival Rate
Pyridinolcarbamate
Lymph Nodes
Morbidity
Intention to Treat Analysis
Thoracic Wall
Etoposide
Tamoxifen
Fluorouracil
Estrogen Receptors
Cisplatin
Breast

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hortobagyi, G. N., Buzdar, A. U., Theriault, R. L., Valero, V., Frye, D., Booser, D. J., ... Champlin, R. E. (2000). Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. Journal of the National Cancer Institute, 92(3), 225-233.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. / Hortobagyi, Gabriel N.; Buzdar, Aman U.; Theriault, Richard L.; Valero, Vicente; Frye, Debra; Booser, Daniel J.; Holmes, Frankie A.; Giralt, Sergio; Khouri, Issa; Andersson, Borje; Gajewski, James L.; Rondon, Gabriela; Smith, Terry L.; Singletary, Sonja E.; Ames, Frederick C.; Sneige, Nour; Strom, Eric A.; McNeese, Marsha D.; Deisseroth, Albert B.; Champlin, Richard E.

In: Journal of the National Cancer Institute, Vol. 92, No. 3, 02.02.2000, p. 225-233.

Research output: Contribution to journalArticle

Hortobagyi, GN, Buzdar, AU, Theriault, RL, Valero, V, Frye, D, Booser, DJ, Holmes, FA, Giralt, S, Khouri, I, Andersson, B, Gajewski, JL, Rondon, G, Smith, TL, Singletary, SE, Ames, FC, Sneige, N, Strom, EA, McNeese, MD, Deisseroth, AB & Champlin, RE 2000, 'Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma', Journal of the National Cancer Institute, vol. 92, no. 3, pp. 225-233.
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. Journal of the National Cancer Institute. 2000 Feb 2;92(3):225-233.
Hortobagyi, Gabriel N. ; Buzdar, Aman U. ; Theriault, Richard L. ; Valero, Vicente ; Frye, Debra ; Booser, Daniel J. ; Holmes, Frankie A. ; Giralt, Sergio ; Khouri, Issa ; Andersson, Borje ; Gajewski, James L. ; Rondon, Gabriela ; Smith, Terry L. ; Singletary, Sonja E. ; Ames, Frederick C. ; Sneige, Nour ; Strom, Eric A. ; McNeese, Marsha D. ; Deisseroth, Albert B. ; Champlin, Richard E. / Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. In: Journal of the National Cancer Institute. 2000 ; Vol. 92, No. 3. pp. 225-233.
@article{8db8972666ab44808df335fa148bbfb8,
title = "Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma",
abstract = "Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. Patients and Methods: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. Results: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty- nine patients were randomly assigned to FAC and 39 to FAC followed by high- dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62{\%} and 48{\%} for FAC and FAC/high-dose chemotherapy, respectively (P = .35), and 3-year survival rates were 77{\%} and 58{\%}, respectively (P = .23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. Conclusions: No relapse- free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.",
author = "Hortobagyi, {Gabriel N.} and Buzdar, {Aman U.} and Theriault, {Richard L.} and Vicente Valero and Debra Frye and Booser, {Daniel J.} and Holmes, {Frankie A.} and Sergio Giralt and Issa Khouri and Borje Andersson and Gajewski, {James L.} and Gabriela Rondon and Smith, {Terry L.} and Singletary, {Sonja E.} and Ames, {Frederick C.} and Nour Sneige and Strom, {Eric A.} and McNeese, {Marsha D.} and Deisseroth, {Albert B.} and Champlin, {Richard E.}",
year = "2000",
month = "2",
day = "2",
language = "English (US)",
volume = "92",
pages = "225--233",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

AU - Hortobagyi, Gabriel N.

AU - Buzdar, Aman U.

AU - Theriault, Richard L.

AU - Valero, Vicente

AU - Frye, Debra

AU - Booser, Daniel J.

AU - Holmes, Frankie A.

AU - Giralt, Sergio

AU - Khouri, Issa

AU - Andersson, Borje

AU - Gajewski, James L.

AU - Rondon, Gabriela

AU - Smith, Terry L.

AU - Singletary, Sonja E.

AU - Ames, Frederick C.

AU - Sneige, Nour

AU - Strom, Eric A.

AU - McNeese, Marsha D.

AU - Deisseroth, Albert B.

AU - Champlin, Richard E.

PY - 2000/2/2

Y1 - 2000/2/2

N2 - Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. Patients and Methods: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. Results: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty- nine patients were randomly assigned to FAC and 39 to FAC followed by high- dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P = .35), and 3-year survival rates were 77% and 58%, respectively (P = .23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. Conclusions: No relapse- free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.

AB - Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy. Patients and Methods: Patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible. All patients were to receive eight cycles of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC). Patients were stratified by stage and randomly assigned to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support or no additional chemotherapy. Tamoxifen was planned for postmenopausal patients with estrogen receptor-positive tumors and chest wall radiotherapy was planned for all. All P values are from two-sided tests. Results: Seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy) were registered. Thirty- nine patients were randomly assigned to FAC and 39 to FAC followed by high- dose chemotherapy. After a median follow-up of 6.5 years, there have been 41 relapses. In intention-to-treat analyses, estimated 3-year relapse-free survival rates were 62% and 48% for FAC and FAC/high-dose chemotherapy, respectively (P = .35), and 3-year survival rates were 77% and 58%, respectively (P = .23). Overall, there was greater and more frequent morbidity associated with high-dose chemotherapy than with FAC; there was one septic death associated with high-dose chemotherapy. Conclusions: No relapse- free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. Thus, high-dose chemotherapy is not indicated outside a clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=0034594653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034594653&partnerID=8YFLogxK

M3 - Article

C2 - 10655439

AN - SCOPUS:0034594653

VL - 92

SP - 225

EP - 233

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -